Skip Navigation

Should Patients with Terminal Diseases be Allowed to Try Experimental Drugs?

December 28, 2017

The Goldwater Institute’s Christina Sandefur joins the show to talk about why 2017 was a big year for states doing what Congress hasn’t been able to do: offering suffering patients hope with right-to-try laws.

In this episode of the Heartland Daily Podcast, Goldwater Institute executive vice president Christina Sandefur joins Heartland Institute research fellow Jesse Hathaway to talk about right-to-try laws, a health care policy reform becoming increasingly popular among state legislators and Congressmen.

Right-to-try laws give individuals with terminal diseases the ability to try drugs that have not been approved by the U.S. Food & Drug Administration but have been through initial safety tests, Sandefur says.

Seeing inaction at the national level, an increasing number of states are passing such laws, enabling their residents to have a chance to save their own lives, given that they’re willing to take responsibility for the risks.

Fortunately for everyone, support for a national right-to-try law is also growing, Sandefur says. Sandefur and Hathaway talk about the latest news on the national right-to-try bill, discuss where people can go to find out more about right-to-try, and speak of other important health care reform issues.
Article Tags
Health Care
Author
Jesse Hathaway is the managing editor of Budget & Tax News, a publication of The Heartland Institute.
jhathaway@heartland.org @JesseinOH